Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic information on SLCO1B1 and ABCC2 polymorphisms

Journal of Clinical Pharmacology

Volumn 49, Issue 11, 2009, Pages 1309-1317

  Ide, Takafumi ^a   Sasaki, Tomohiro ^a   Maeda, Kazuya ^b   Higuchi, Shun ^a   Sugiyama, Yuichi ^b   Ieiri, Ichiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

ABCC2; Enterohepatic circulation model; NONMEM; Pravastatin; SLCO1B1

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2; PRAVASTATIN;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENTEROHEPATIC CIRCULATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENOMICS; QUANTITATIVE ANALYSIS;

ADULT; ENTEROHEPATIC CIRCULATION; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MODELS, CARDIOVASCULAR; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION SURVEILLANCE; PRAVASTATIN;

EID: 70350397475     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009341960     Document Type: Article

References (46)

1. Grundy SM HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988 ; 319: 24-33.
2. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991 ; 19: 740-748.
3. Triscari J., OĝDonnell D., Zinny M., Pan HY Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol. 1995 ; 35: 142-144.
4. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000 ; 39: 397-412.
5. Ogawa K., Hasegawa S., Udaka Y., Nara K., Iwai S., Oguchi K. Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects. J Clin Pharmacol. 2003 ; 43: 1268-1273.
6. Abe T., Kakyo M., Tokui T., et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 ; 274: 17159-17163.
7. Hsiang B., Zhu Y., Wang Z., et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 ; 274: 37161-37168.
8. Knig J., Cui Y., Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 2000 ; 278: G156 - G164.
9. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003;1609:1-18.
10. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res. 1996;13:1559-1564.
11. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol. 2006 ; 62: 409-415.
12. Knig J., Seithel A., Gradhand U., Fromm MF Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006 ; 372: 432-443.
13. Tirona RG, Leake BF, Merino G., Kim RB Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001 ; 276: 35669-35675.
14. Kameyama Y., Yamashita K., Kobayashi K., Hosokawa M., Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 ; 15: 513-522.
15. Nozawa T., Minami H., Sugiura S., Tsuji A., Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005 ; 33: 434-439.
16. Nishizato Y., Ieiri I., Suzuki H., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003 ; 73: 554-565.
17. Niemi M., Schaeffeler E., Lang T., et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004 ; 14: 429-440.
18. SEARCH Collaborative Group. SLCO1B1 variants and statininduced myopathy-A genomewide study. N Engl J Med. 2008 ; 359: 789-799.
19. Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta. 1999 ; 1461: 347-357.
20. Yamazaki M., Akiyama S., Niĝinuma K., Nishigaki R., Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997 ; 25: 1123-1129.
21. Kivist KT, Grisk O., Hofmann U., et al. Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. Drug Metab Dispos. 2005 ; 33: 1593-1596.
22. Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001 ; 11: 175-184.
23. Sai K., Saito Y., Itoda M., et al. Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab Pharmacokinet. 2008 ; 23: 139-147.
24. Meyer zu Schwabedissen HE, Jedlitschky G., Gratz M., et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos. 2005 ; 33: 896-904.
25. Naesens M., Kuypers DR, Verbeke K., Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006 ; 82: 1074-1084.
26. Rau T., Erney B., Gres R., Eschenhagen T., Beck J., Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006 ; 80: 468-476.
27. Niemi M., Arnold KA, Backman JT, et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics. 2006 ; 16: 801-808.
28. Choi JH, Ahn BM, Yi J., et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics. 2007 ; 17: 403-415.
29. Haenisch S., Zimmermann U., Dazert E., et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007 ; 7: 56-65.
30. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007 ; 132: 272-281.
31. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecaninduced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007 ; 81: 42-49.
32. Haenisch S., May K., Wegner D., Caliebe A., Cascorbi I., Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics. 2008 ; 18: 357-365.
33. Maeda K., Ieiri I., Yasuda K., et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther. 2006 ; 79: 427-439.
34. Suwannakul S., Ieiri I., Kimura M., et al. Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Hum Genet. 2008 ; 53: 899-904.
35. Jonsson EN, Karlsson MO Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999 ; 58: 51-64.
36. Saint-Marcoux F., Marquet P., Jacqz-Aigrain E., et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet. 2006 ; 45: 905-922.
37. Yamasaki Y., Ieiri I., Kusuhara H., et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther. 2008 ; 84: 95-103.
38. Savic RM, Jonker DM, Kerbusch T., Karlsson MO Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007 ; 34: 711-726.
39. Hooker AC, Staatz CE, Karlsson MO Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007 ; 24: 2187-2197.
40. Lindbom L., Ribbing J., Jonsson EN Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004 ; 75: 85-94.
41. Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. J Pharm Pharmacol. 1999 ; 51: 1143-1148.
42. Jiao Z., Ding JJ, Shen J., et al. Population pharmacokinetic modeling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol. 2008 ; 65: 893-907.
43. Takane H., Miyata M., Burioka N., et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet. 2006 ; 51: 822-826.
44. Zhang W., Chen BL, Ozdemir V., et al. SLCO1B1 521T>C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol. 2007 ; 64: 647-656.
45. Watanabe T., Kusuhara H., Maeda K., Shitara Y., Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009 ; 328: 652-662.
46. Ho RH, Choi L., Lee W., et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007 ; 17: 647-656.